Global Acute Lymphocytic Leukemia Market: Trend Analysis and Forecast to 2022


Select Your License Type


samplerequest
makeanenquiry
download



                                 

                                                 Figure : Global Acute Lymphocytic Leukemia Market By Region


Acute Lymphocytic Leukemia (ALL) is also known as acute lymphoblastic leukemia, is a cancer of white blood cell or bone marrow, which occurs due to overproduction and accumulation of cancerous white blood cell, known as lymphoblasts. ALL is an acute form of leukemia which majorly affects the lymphoid system, blood and bone marrow. This type of leukemia is more dominant in infants, however, it can be also diagnosed in adults. The common symptoms of ALL a patient exhibits are weakness, tiredness, dizziness, fever, shortness of breath, frequent infections, bruising, and bleeding. Globally, the growing awareness about ALL among the consumers has primarily driven the demand for drugs and treatment of acute lymphocytic leukemia. In 2015, the size of global acute lymphocytic leukemia market was valued at USD XX million. The value of global acute lymphocytic leukemia market is projected to grow with a CAGR between 4.0% – 5.0% during the forecast period of 2016-2022 and reach USD XX million by 2022.

The growth in acute lymphocytic leukemia market is primarily driven by unmet healthcare needs coupled with innovative therapies. Moreover, provision for orphan drugs is majorly contributing to the growth of this market. However, High cost of production, adverse effect of drugs and entry of generics are considered to be the major restraining factors that are likely to hinder the growth of this market over the forecast period. Yet, the global acute lymphocytic leukemia market is expected to present several opportunities to the leading players in the market over the forecast period, due to growing unmet healthcare needs and minimal competition.

Segments Covered:

The report segments the acute lymphocytic leukemia market by therapeutics, by rout of administration, by types of molecule and by region. Market segmentation based on therapeutics includes existing drugs and pipeline drugs. Existing drugs are further sub segmented into CALGB 8811 regimen, hyper CVD regimen, linker regimen, nucleoside regimen and oncasper; Pipeline drugs are further sub segmented into margibo, graspa, inotuzumab ozogamicin. Based on route of administration, market segmented into oral and parental. Types of molecules segment comprise biologics and small molecules.

Geographic Coverage and Analysis

The report provides regional analysis covering geographies such as North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is the largest acute lymphocytic leukemia market globally, with a market share of more than XX%. The market growth in North America is majorly driven by the large number of patients detected with ALL in this region, especially in the U.S. Europe is the second largest market for ALL; growth in this region is attributed to special provision for orphan drugs by European Medicine Agency due to which vendors enjoy ten years of market exclusivity for their products. However, Asia pacific is anticipated to grow at fastest CAGR of 5.X% over the forecast period. This is due to rise in public awareness about the disease that will propel the market growth.

Companies Profiled:

The companies covered in the report include

  • ERYTECH Pharma,
  • Talon Therapeutic, Inc.,
  • Pfizer Inc.
  • GlaxoSmithKline plc,
  • Sigma-Tau Pharmaceuticals, Inc., and
  • Genzyme Corporation

Report Highlights:

The report provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report provides insights on the factors that are driving and restraining the demand of acute lymphocytic leukemia globally as well as regionally. Moreover, IGR-Growth Matrix analysis given in the report brings an insight on the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter’s five forces analysis and value chain analysis of acute lymphocytic leukemia market. Moreover, the study highlights current market trends and provides forecast from 2016 to 2022. We also have highlighted future trends in the acute lymphocytic leukemia market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight on the market share of the leading players. Additionally, the analysis highlights rise and fall in the market shares of the key players in the market.

The report also provides in depth analysis of regulatory framework pertaining to Acute Lymphocytic Leukemia Market. This will help the companies to understand the regulatory compliances, supports, barriers in the Acute Lymphocytic Leukemia market.  This section highlights key amendments and their implication on Acute Lymphocytic Leukemia market in the short run as well as in the long run.This report will help manufacturers, suppliers and distributors of the acute lymphocytic leukemia market to understand the present and future trends in this market and formulate their strategies accordingly.

1.    Report Overview

1.1    Report Description
1.2    Research Methods
1.3    Research Approaches

2.    Executive Summary

3.    Acute Lymphocytic Leukemia Market Overview

3.1    Introduction
3.2    Market Dynamics
3.3    Drivers
3.4    Restraints
3.5    Opportunities
3.6    Challenges
3.7    Porter’s Five Forces Analysis
3.8    IGR – Growth Matrix Analysis
3.9    Competitive Landscape in the Acute Lymphocytic Leukemia Market
3.10 : Regulatory Framework analysis by region

3.10.1: North America
3.10.2 Europe
3.10.3 RoW (Including APAC, and LATAM)

4.    Global Acute Lymphocytic Leukemia Market, by Therapeutics, (USD Million) 2015 – 2022

4.1    Introduction
4.2    Existing Drugs

4.2.1    CALGB 8811 regimen
4.2.2    Hyper CVD regimen
4.2.3    Linker regimen
4.2.4    Nucleoside regimen
4.2.5    Oncasper

4.3    Pipeline drugs

4.3.1    Margibo
4.3.2    Graspa
4.3.3    Inotuzumab ozogamicin

5.    Global Acute Lymphocytic Leukemia Market, by Route of administration, (USD Million) 2015 – 2022

5.1    Introduction
5.2    Oral
5.3    Parental

6.    Global Acute Lymphocytic Leukemia Market, by molecule type, (USD Million) 2015 – 2022

6.1    Introduction
6.2    Biologics
6.3    Small molecule
6.4    Ambulatory Clinics
6.5    Home Healthcare

7.    Global Acute Lymphocytic Leukemia Market, by Region, (USD Million) 2015 – 2022

7.1    Introduction
7.2    North America

7.2.1    North America Acute Lymphocytic Leukemia Market, by Therapeutics Type (USD Million)
7.2.2    North America Acute Lymphocytic Leukemia Market, by Route of Administration (USD Million)
7.2.3    North America Acute Lymphocytic Leukemia Market, by Molecule Type (USD Million)

7.3    Europe

7.3.1    Europe Acute Lymphocytic Leukemia Market, by Therapeutics Type (USD Million)
7.3.2    Europe Acute Lymphocytic Leukemia Market, by Route of Administration (USD Million)
7.3.3    Europe Acute Lymphocytic Leukemia Market, by Molecule Type (USD Million)

7.4    Asia Pacific

7.4.1    Asia Pacific Acute Lymphocytic Leukemia Market, by Therapeutics Type (USD Million)
7.4.2    Asia Pacific Acute Lymphocytic Leukemia Market, by Route of Administration (USD Million)
7.4.3    Asia Pacific Acute Lymphocytic Leukemia Market, by Molecule Type (USD Million)

7.5    Latin America

7.5.1    Latin America Acute Lymphocytic Leukemia Market, by Therapeutics Type (USD Million)
7.5.2    Latin America Acute Lymphocytic Leukemia Market, by Route of Administration (USD Million)
7.5.3    Latin America Acute Lymphocytic Leukemia Market, by Molecule Type (USD Million)

7.6    Rest of the World

7.6.1    Row Acute Lymphocytic Leukemia Market, by Therapeutics Type (USD Million)
7.6.2    Row Acute Lymphocytic Leukemia Market, by Route of Administration (USD Million)
7.6.3    Row Acute Lymphocytic Leukemia Market, by Molecule Type (USD Million)

8.    Leading Companies

8.1    Company Profiles
8.1.1    ERYTECH Pharma
8.1.2    Talon Therapeutic, Inc
8.1.3    GlaxoSmithKline plc,
8.1.4    Sigma-Tau Pharmaceuticals, Inc.
8.1.5    Genzyme Corporation


Got a Question?

If you have a question to ask our analyst, just fill this form and send it across, our representative will get in touch with you shortly.